The FDA has granted an orphan drug designation to PV-10, Provectus BioPharmaceuticals’ ocular melanoma treatment candidate, according to a press release.
Rose bengal disodium, also called PV-10, is a small molecule oncolytic immunotherapy delivered via intratumoral injection, which can yield immunogenic cell death in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells.
Preliminary data from a phase 1 basket study of PV-10 in four patients with metastatic cancer to the liver yielded tumor reduction in five of six injected tumors. The data were presented at
Uncategorized